Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$24 Mln
P/E Ratio
--
P/B Ratio
59.1
Industry P/E
--
Debt to Equity
0.22
ROE
-226.64 %
ROCE
-346.41 %
Div. Yield
0 %
Book Value
0.16
EPS
-0.69
CFO
$-73.26 Mln
EBITDA
$-80.04 Mln
Net Profit
$-81.70 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Cyclo Therapeutics (CYTH)
| 22.14 | -6.29 | 26.42 | -48.53 | -36.77 | -49.06 | -35.06 |
|
BSE Sensex*
| 1.48 | 4.01 | 3.03 | 8.65 | 11.66 | 20.20 | 11.03 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Cyclo Therapeutics (CYTH)
| -62.59 | 11.97 | -61.93 | -14.25 | -87.21 | -57.10 | 128.57 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 58.65 | 11,346.08 | 26.77 | 8.05 | |
| 62.90 | 6,566.51 | 50.6 | 23.56 | |
| 56.80 | 11,265.03 | 388.07 | 0.76 | |
| 7.57 | 9,024.30 | -- | -3.24 |
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta... cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida. Cyclo Therapeutics, Inc. is a subsidiary of Rafael Holdings, Inc. Address: 6714 NW 16th Street, Gainesville, FL, United States, 32653 Read more
CEO & Director
Mr. N. Scott Fine
CEO & Director
Mr. N. Scott Fine
Headquarters
Gainesville, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Cyclo Therapeutics Inc (CYTH) stood at $ 13 Mln as on 31-Dec-24
The share price of Cyclo Therapeutics Inc (CYTH) is $0.72 (NASDAQ) as of 27-Mar-2025 09:30 EDT. Cyclo Therapeutics Inc (CYTH) has given a return of -36.77% in the last 3 years.
Cyclo Therapeutics Inc (CYTH) has a market capitalisation of $ 24 Mln as on 27-Mar-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Cyclo Therapeutics Inc (CYTH) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Cyclo Therapeutics Inc (CYTH) and enter the required number of quantities and click on buy to purchase the shares of Cyclo Therapeutics Inc (CYTH).
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida. Cyclo Therapeutics, Inc. is a subsidiary of Rafael Holdings, Inc. Address: 6714 NW 16th Street, Gainesville, FL, United States, 32653
The CEO & director of Mr. N. Scott Fine. is Cyclo Therapeutics Inc (CYTH), and CFO & Sr. VP is Mr. N. Scott Fine.
There is no promoter pledging in Cyclo Therapeutics Inc (CYTH).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,131
|
|
|
1,128
|
|
|
882
|
|
|
682
|
| Cyclo Therapeutics Inc. (CYTH) | Ratios |
|---|---|
|
Return on equity(%)
|
-421.64
|
|
Operating margin(%)
|
-1862.69
|
|
Net Margin(%)
|
-1863.36
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Cyclo Therapeutics Inc (CYTH) was $0 Mln.
